Inhibition of calpain-regulated p35/cdk5 plays a central role in sildenafil-induced protection against chemical hypoxia produced by malonate

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1832, Issue 6, 2013, Pages 705-717

  Barros Miñones, Lucía ^a   Martín de Saavedra, Dolores ^c   Perez Alvarez, Sergio ^b   Orejana, Lourdes ^a   Suquía, Verónica ^a   Goñi Allo, Beatriz ^a   Hervias, Isabel ^a   López, Manuela G ^c   Jordan, Joaquin ^b   Aguirre, Norberto ^a   Puerta, Elena ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b Universidad Castilla La Mancha   (Spain)

^c INSTITUTO TEÓFILO HERNANDO   (Spain)

Author keywords

Apoptosis; Calpain; Cyclin dependent kinase 5 (cdk5); Excitotoxicity; Malonate; Sildenafil

Indexed keywords

CALPAIN; CYCLIN DEPENDENT KINASE 5; MALONIC ACID; MYOCYTE ENHANCER FACTOR 2; PROTEIN P35; SILDENAFIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEATH; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; HYPOXIA; MALE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN PHOSPHORYLATION; RAT;

ANIMALS; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; CALPAIN; CYCLIN-DEPENDENT KINASE 5; HYPOXIA, BRAIN; MALE; MALONATES; NEUROPROTECTIVE AGENTS; PHOSPHODIESTERASE 5 INHIBITORS; PHOSPHORYLATION; PIPERAZINES; PURINES; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; SIGNAL TRANSDUCTION; SULFONES; TAU PROTEINS;

EID: 84875067216     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2013.02.002     Document Type: Article

References (87)

1. Bender A.T., Beavo J.A. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol. Rev. 2006, 58:488-520.
2. Bender A.T., Beavo J.A. Specific localized expression of cGMP PDEs in Purkinje neurons and macrophages. Neurochem. Int. 2004, 45:853-857.
3. Wang L., Gang Zhang Z., Lan Zhang R., Chopp M. Activation of the PI3-K/Akt pathway mediates cGMP enhanced-neurogenesis in the adult progenitor cells derived from the subventricular zone. J. Cereb. Blood Flow Metab. 2005, 25:1150-1158.
4. Kouvelas D., Goulas A., Papazisis G., Sardeli C., Pourzitaki C. PDE5 inhibitors: in vitro and in vivo pharmacological profile. Curr. Pharm. Des. 2009, 15:3464-3475.
5. Kukreja R.C., Salloum F.N., Das A., Koka S., Ockaili R.A., Xi L. Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases. Exp. Clin. Cardiol. 2011, 16:e30-e35.
6. Ding G., Jiang Q., Li L., Zhang L., Zhang Z.G., Ledbetter K.A., Panda S., Davarani S.P., Athiraman H., Li Q., Ewing J.R., Chopp M. Magnetic resonance imaging investigation of axonal remodeling and angiogenesis after embolic stroke in sildenafil-treated rats. J. Cereb. Blood Flow Metab. 2008, 28:1440-1448.
7. Li L., Jiang Q., Zhang L., Ding G., Gang Zhang Z., Li Q., Ewing J.R., Lu M., Panda S., Ledbetter K.A., Whitton P.A., Chopp M. Angiogenesis and improved cerebral blood flow in the ischemic boundary area detected by MRI after administration of sildenafil to rats with embolic stroke. Brain Res. 2007, 1132:185-192.
8. Menniti F.S., Ren J., Coskran T.M., Liu J., Morton D., Sietsma D.K., Som A., Stephenson D.T., Tate B.A., Finklestein S.P. Phosphodiesterase 5A inhibitors improve functional recovery after stroke in rats: optimized dosing regimen with implications for mechanism. J. Pharmacol. Exp. Ther. 2009, 331:842-850.
9. Zhang R. Sildenafil (Viagra) induces neurogenesis and promotes functional recovery after stroke in rats. Stroke 2002, 33:2675-2680.
10. Zhang L., Zhang R.L., Wang Y., Zhang C., Zhang Z.G., Meng H., Chopp M. Functional recovery in aged and young rats after embolic stroke: treatment with a phosphodiesterase type 5 inhibitor. Stroke 2005, 36:847-852.
11. Zhang R.L., Zhang Z., Zhang L., Wang Y., Zhang C., Chopp M. Delayed treatment with sildenafil enhances neurogenesis and improves functional recovery in aged rats after focal cerebral ischemia. J. Neurosci. Res. 2006, 83:1213-1219.
12. Silver B., McCarthy S., Lu M., Mitsias P., Russman A.N., Katramados A., Morris D.C., Lewandowski C.A., Chopp M. Sildenafil treatment of subacute ischemic stroke: a safety study at 25-mg daily for 2weeks. J. Stroke Cerebrovasc. Dis. 2009, 18:381-383.
13. Schulz J.B., Weller M., Matthews R.T., Heneka M.T., Groscurth P., Martinou J.C., Lommatzsch J., von Coelln R., Wullner U., Loschmann P.A., Beal M.F., Dichgans J., Klockgether T. Extended therapeutic window for caspase inhibition and synergy with MK-801 in the treatment of cerebral histotoxic hypoxia. Cell Death Differ. 1998, 5:847-857.
14. Dedeoglu A., Ferrante R.J., Andreassen O.A., Dillmann W.H., Beal M.F. Mice overexpressing 70-kDa heat shock protein show increased resistance to malonate and 3-nitropropionic acid. Exp. Neurol. 2002, 176:262-265.
15. Greene J.G., Greenamyre J.T. Manipulation of membrane potential modulates malonate-induced striatal excitotoxicity in vivo. J. Neurochem. 1996, 66:637-643.
16. Aarts M.M., Arundine M., Tymianski M. Novel concepts in excitotoxic neurodegeneration after stroke. Expert Rev. Mol. Med. 2003, 5:1-22.
17. Arundine M., Tymianski M. Molecular mechanisms of calcium-dependent neurodegeneration in excitotoxicity. Cell Calcium 2003, 34:325-337.
18. Slevin M., Krupinski J. Cyclin-dependent kinase-5 targeting for ischaemic stroke. Curr. Opin. Pharmacol. 2009, 9:119-124.
19. Rashidian J., Iyirhiaro G., Aleyasin H., Rios M., Vincent I., Callaghan S., Bland R.J., Slack R.S., During M.J., Park D.S. Multiple cyclin-dependent kinases signals are critical mediators of ischemia/hypoxic neuronal death in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:14080-14085.
20. Patrick G.N., Zukerberg L., Nikolic M., de la Monte S., Dikkes P., Tsai L.H. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 1999, 402:615-622.
21. Lee M.S., Kwon Y.T., Li M., Peng J., Friedlander R.M., Tsai L.H. Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature 2000, 405:360-364.
22. Kusakawa G., Saito T., Onuki R., Ishiguro K., Kishimoto T., Hisanaga S. Calpain-dependent proteolytic cleavage of the p35 cyclin-dependent kinase 5 activator to p25. J. Biol. Chem. 2000, 275:17166-17172.
23. Camins A., Verdaguer E., Folch J., Pallas M. Involvement of calpain activation in neurodegenerative processes. CNS Drug Rev. 2006, 12:135-148.
24. Timsit S., Menn B. Cerebral ischemia, cell cycle elements and Cdk5. Biotechnol. J. 2007, 2:958-966.
25. Menn B., Bach S., Blevins T.L., Campbell M., Meijer L., Timsit S. Delayed treatment with systemic (S)-roscovitine provides neuroprotection and inhibits in vivo CDK5 activity increase in animal stroke models. PLoS One 2010, 5:e12117.
26. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1997, Academic Press, New York.
27. Puerta E., Hervias I., Barros-Minones L., Jordan J., Ricobaraza A., Cuadrado-Tejedor M., Garcia-Osta A., Aguirre N. Sildenafil protects against 3-nitropropionic acid neurotoxicity through the modulation of calpain, CREB, and BDNF. Neurobiol. Dis. 2010, 38:237-245.
28. Reagan-Shaw S., Nihal M., Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008, 22:659-661.
29. Puerta E., Hervias I., Goni-Allo B., Lasheras B., Jordan J., Aguirre N. Phosphodiesterase 5 inhibitors prevent 3,4-methylenedioxymethamphetamine-induced 5-HT deficits in the rat. J. Neurochem. 2009, 108:755-766.
30. Goni-Allo B., Ramos M., Jordan J., Aguirre N. In vivo studies on the protective role of minocycline against excitotoxicity caused by malonate or N-methyl-d-aspartate. Exp. Neurol. 2005, 191:326-330.
31. Garcia-Osta A., Del Rio J., Frechilla D. Increased CRE-binding activity and tryptophan hydroxylase mRNA expression induced by 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") in the rat frontal cortex but not in the hippocampus. Brain Res. Mol. Brain Res. 2004, 126:181-187.
32. Pallotti F., Lenaz G. Isolation and subfractionation of mitochondria from animal cells and tissue culture lines. Methods Cell Biol. 2007, 80:3-44.
33. Vijayvergiya C., Beal M.F., Buck J., Manfredi G. Mutant superoxide dismutase 1 forms aggregates in the brain mitochondrial matrix of amyotrophic lateral sclerosis mice. J. Neurosci. 2005, 25:2463-2470.
34. Goni-Allo B., Puerta E., Mathuna B.O., Hervias I., Lasheras B., de la Torre R., Aguirre N. On the role of tyrosine and peripheral metabolism in 3,4-methylenedioxymethamphetamine-induced serotonin neurotoxicity in rats. Neuropharmacology 2008, 54:885-900.
35. Egea J., Rosa A.O., Sobrado M., Gandia L., Lopez M.G., Garcia A.G. Neuroprotection afforded by nicotine against oxygen and glucose deprivation in hippocampal slices is lost in alpha7 nicotinic receptor knockout mice. Neuroscience 2007, 145:866-872.
36. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65:55-63.
37. Sobrado M., Roda J.M., Lopez M.G., Egea J., Garcia A.G. Galantamine and memantine produce different degrees of neuroprotection in rat hippocampal slices subjected to oxygen-glucose deprivation. Neurosci. Lett. 2004, 365:132-136.
38. Ha H.C., Woster P.M., Yager J.D., Casero R.A. The role of polyamine catabolism in polyamine analogue-induced programmed cell death. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:11557-11562.
39. Araujo I.M., Carreira B.P., Carvalho C.M., Carvalho A.P. Calpains and delayed calcium deregulation in excitotoxicity. Neurochem. Res. 2010, 35:1966-1969.
40. Szydlowska K., Tymianski M. Calcium, ischemia and excitotoxicity. Cell Calcium 2010, 47:122-129.
41. O'Hare M.J., Kushwaha N., Zhang Y., Aleyasin H., Callaghan S.M., Slack R.S., Albert P.R., Vincent I., Park D.S. Differential roles of nuclear and cytoplasmic cyclin-dependent kinase 5 in apoptotic and excitotoxic neuronal death. J. Neurosci. 2005, 25:8954-8966.
42. Rami A., Ferger D., Krieglstein J. Blockade of calpain proteolytic activity rescues neurons from glutamate excitotoxicity. Neurosci. Res. 1997, 27:93-97.
43. Meijer L., Borgne A., Mulner O., Chong J.P., Blow J.J., Inagaki N., Inagaki M., Delcros J.G., Moulinoux J.P. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur. J. Biochem. 1997, 243:527-536.
44. Augustinack J.C., Schneider A., Mandelkow E.M., Hyman B.T. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol. 2002, 103:26-35.
45. Emerson C.P. Myogenesis and developmental control genes. Curr. Opin. Cell Biol. 1990, 2:1065-1075.
46. Rashidian J., Rousseaux M.W., Venderova K., Qu D., Callaghan S.M., Phillips M., Bland R.J., During M.J., Mao Z., Slack R.S., Park D.S. Essential role of cytoplasmic cdk5 and Prx2 in multiple ischemic injury models, in vivo. J. Neurosci. 2009, 29:12497-12505.
47. Gomez-Lazaro M., Galindo M.F., Melero-Fernandez de Mera R.M., Fernandez-Gomez F.J., Concannon C.G., Segura M.F., Comella J.X., Prehn J.H., Jordan J. Reactive oxygen species and p38 mitogen-activated protein kinase activate Bax to induce mitochondrial cytochrome c release and apoptosis in response to malonate. Mol. Pharmacol. 2007, 71:736-743.
48. Fernandez-Gomez F.J., Galindo M.F., Gomez-Lazaro M., Yuste V.J., Comella J.X., Aguirre N., Jordan J. Malonate induces cell death via mitochondrial potential collapse and delayed swelling through an ROS-dependent pathway. Br. J. Pharmacol. 2005, 144:528-537.
49. Yang L., Sugama S., Mischak R.P., Kiaei M., Bizat N., Brouillet E., Joh T.H., Beal M.F. A novel systemically active caspase inhibitor attenuates the toxicities of MPTP, malonate, and 3NP in vivo. Neurobiol. Dis. 2004, 17:250-259.
50. Taylor R.C., Cullen S.P., Martin S.J. Apoptosis: controlled demolition at the cellular level. Nat. Rev. Mol. Cell Biol. 2008, 9:231-241.
51. Korsmeyer S.J., Wei M.C., Saito M., Weiler S., Oh K.J., Schlesinger P.H. Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c. Cell Death Differ. 2000, 7:1166-1173.
52. Galluzzi L., Blomgren K., Kroemer G. Mitochondrial membrane permeabilization in neuronal injury. Nat. Rev. Neurosci. 2009, 10:481-494.
53. Henshaw R., Jenkins B.G., Schulz J.B., Ferrante R.J., Kowall N.W., Rosen B.R., Beal M.F. Malonate produces striatal lesions by indirect NMDA receptor activation. Brain Res. 1994, 647:161-166.
54. Barros-Minones L., Orejana L., Goni-Allo B., Suquia V., Hervias I., Aguirre N., Puerta E. Modulation of the ASK1-MKK3/6-p38/MAPK signalling pathway mediates sildenafil protection against chemical hypoxia caused by malonate. Br. J. Pharmacol. 2012.
55. Arundine M., Tymianski M. Molecular mechanisms of glutamate-dependent neurodegeneration in ischemia and traumatic brain injury. Cell. Mol. Life Sci. 2004, 61:657-668.
56. Fan M.M., Raymond L.A. N-methyl-D-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease. Prog. Neurobiol. 2007, 81:272-293.
57. Lau A., Tymianski M. Glutamate receptors, neurotoxicity and neurodegeneration. Pflugers Arch. 2010, 460:525-542.
58. Waxman E.A., Lynch D.R. N-methyl-D-aspartate receptor subtypes: multiple roles in excitotoxicity and neurological disease. Neuroscientist 2005, 11:37-49.
59. Takano J., Tomioka M., Tsubuki S., Higuchi M., Iwata N., Itohara S., Maki M., Saido T.C. Calpain mediates excitotoxic DNA fragmentation via mitochondrial pathways in adult brains: evidence from calpastatin mutant mice. J. Biol. Chem. 2005, 280:16175-16184.
60. Jordan J., Galindo M.F., Miller R.J. Role of calpain- and interleukin-1 beta converting enzyme-like proteases in the beta-amyloid-induced death of rat hippocampal neurons in culture. J. Neurochem. 1997, 68:1612-1621.
61. Nath R., Davis M., Probert A.W., Kupina N.C., Ren X., Schielke G.P., Wang K.K. Processing of cdk5 activator p35 to its truncated form (p25) by calpain in acutely injured neuronal cells. Biochem. Biophys. Res. Commun. 2000, 274:16-21.
62. Patzke H., Tsai L.H. Calpain-mediated cleavage of the cyclin-dependent kinase-5 activator p39 to p29. J. Biol. Chem. 2002, 277:8054-8060.
63. Hisanaga S., Endo R. Regulation and role of cyclin-dependent kinase activity in neuronal survival and death. J. Neurochem. 2010, 115:1309-1321.
64. Wang J., Liu S., Fu Y., Wang J.H., Lu Y. Cdk5 activation induces hippocampal CA1 cell death by directly phosphorylating NMDA receptors. Nat. Neurosci. 2003, 6:1039-1047.
65. Mitsios N., Pennucci R., Krupinski J., Sanfeliu C., Gaffney J., Kumar P., Kumar S., Juan-Babot O., Slevin M. Expression of cyclin-dependent kinase 5 mRNA and protein in the human brain following acute ischemic stroke. Brain Pathol. 2007, 17:11-23.
66. Li B.S., Sun M.K., Zhang L., Takahashi S., Ma W., Vinade L., Kulkarni A.B., Brady R.O., Pant H.C. Regulation of NMDA receptors by cyclin-dependent kinase-5. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:12742-12747.
67. Kanungo J., Zheng Y.L., Amin N.D., Pant H.C. Targeting Cdk5 activity in neuronal degeneration and regeneration. Cell. Mol. Neurobiol. 2009, 29:1073-1080.
68. Camins A., Verdaguer E., Folch J., Canudas A.M., Pallas M. The role of CDK5/P25 formation/inhibition in neurodegeneration. Drug News Perspect. 2006, 19:453-460.
69. Wen Y., Yang S.H., Liu R., Perez E.J., Brun-Zinkernagel A.M., Koulen P., Simpkins J.W. Cdk5 is involved in NFT-like tauopathy induced by transient cerebral ischemia in female rats. Biochim. Biophys. Acta 2007, 1772:473-483.
70. Morioka M., Kawano T., Yano S., Kai Y., Tsuiki H., Yoshinaga Y., Matsumoto J., Maeda T., Hamada J., Yamamoto H., Fukunaga K., Kuratsu J. Hyperphosphorylation at serine 199/202 of tau factor in the gerbil hippocampus after transient forebrain ischemia. Biochem. Biophys. Res. Commun. 2006, 347:273-278.
71. Heidenreich K.A., Linseman D.A. Myocyte enhancer factor-2 transcription factors in neuronal differentiation and survival. Mol. Neurobiol. 2004, 29:155-166.
72. Tang X., Wang X., Gong X., Tong M., Park D., Xia Z., Mao Z. Cyclin-dependent kinase 5 mediates neurotoxin-induced degradation of the transcription factor myocyte enhancer factor 2. J. Neurosci. 2005, 25:4823-4834.
73. Gong X., Tang X., Wiedmann M., Wang X., Peng J., Zheng D., Blair L.A., Marshall J., Mao Z. Cdk5-mediated inhibition of the protective effects of transcription factor MEF2 in neurotoxicity-induced apoptosis. Neuron 2003, 38:33-46.
74. Verdaguer E., Alvira D., Jimenez A., Rimbau V., Camins A., Pallas M. Inhibition of the cdk5/MEF2 pathway is involved in the antiapoptotic properties of calpain inhibitors in cerebellar neurons. Br. J. Pharmacol. 2005, 145:1103-1111.
75. Okamoto S., Li Z., Ju C., Scholzke M.N., Mathews E., Cui J., Salvesen G.S., Bossy-Wetzel E., Lipton S.A. Dominant-interfering forms of MEF2 generated by caspase cleavage contribute to NMDA-induced neuronal apoptosis. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:3974-3979.
76. Gregoire S., Tremblay A.M., Xiao L., Yang Q., Ma K., Nie J., Mao Z., Wu Z., Giguere V., Yang X.J. Control of MEF2 transcriptional activity by coordinated phosphorylation and sumoylation. J. Biol. Chem. 2006, 281:4423-4433.
77. Cox D.M., Du M., Marback M., Yang E.C., Chan J., Siu K.W., McDermott J.C. Phosphorylation motifs regulating the stability and function of myocyte enhancer factor 2A. J. Biol. Chem. 2003, 278:15297-15303.
78. Yin Y., She H., Li W., Yang Q., Guo S., Mao Z. Modulation of neuronal survival factor MEF2 by kinases in Parkinson's disease. Front. Physiol. 2012, 3:171.
79. Molkentin J.D., Li L., Olson E.N. Phosphorylation of the MADS-Box transcription factor MEF2C enhances its DNA binding activity. J. Biol. Chem. 1996, 271:17199-17204.
80. Levine B., Sinha S., Kroemer G. Bcl-2 family members: dual regulators of apoptosis and autophagy. Autophagy 2008, 4:600-606.
81. Gibson M.E., Han B.H., Choi J., Knudson C.M., Korsmeyer S.J., Parsadanian M., Holtzman D.M. BAX contributes to apoptotic-like death following neonatal hypoxia-ischemia: evidence for distinct apoptosis pathways. Mol. Med. 2001, 7:644-655.
82. Toulmond S., Tang K., Bureau Y., Ashdown H., Degen S., O'Donnell R., Tam J., Han Y., Colucci J., Giroux A., Zhu Y., Boucher M., Pikounis B., Xanthoudakis S., Roy S., Rigby M., Zamboni R., Robertson G.S., Ng G.Y., Nicholson D.W., Fluckiger J.P. Neuroprotective effects of M826, a reversible caspase-3 inhibitor, in the rat malonate model of Huntington's disease. Br. J. Pharmacol. 2004, 141:689-697.
83. Andreassen O.A., Ferrante R.J., Hughes D.B., Klivenyi P., Dedeoglu A., Ona V.O., Friedlander R.M., Beal M.F. Malonate and 3-nitropropionic acid neurotoxicity are reduced in transgenic mice expressing a caspase-1 dominant-negative mutant. J. Neurochem. Aug 2000, 75(2):847-852.
84. Sasaki T., Kitagawa K., Yagita Y., Sugiura S., Omura-Matsuoka E., Tanaka S., Matsushita K., Okano H., Tsujimoto Y., Hori M. Bcl2 enhances survival of newborn neurons in the normal and ischemic hippocampus. J. Neurosci. Res. 2006, 84:1187-1196.
85. Pugazhenthi S., Nesterova A., Sable C., Heidenreich K.A., Boxer L.M., Heasley L.E., Reusch J.E. Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein. J. Biol. Chem. 2000, 275:10761-10766.
86. Das A., Xi L., Kukreja R.C. Protein kinase G-dependent cardioprotective mechanism of phosphodiesterase-5 inhibition involves phosphorylation of ERK and GSK3beta. J. Biol. Chem. 2008, 283:29572-29585.
87. Schulz J.B., Matthews R.T., Jenkins B.G., Brar P., Beal M.F. Improved therapeutic window for treatment of histotoxic hypoxia with a free radical spin trap. J. Cereb. Blood Flow Metab. 1995, 15:948-952.